This new physical extension of QPS’ Dermal and Transdermal Research Services portfolio will further strengthen the company’s ability to assist clients in moving their dermal and transdermal products from preclinical evaluations through to late stage clinical development.
“With QPS’ increasing early phase clinical presence in topical and transdermal pharmacokinetics and bioequivalence, this is a logical step in the evolution of our Dermal and Transdermal Research Services Division,” said Ben Chien, QPS President and CEO.
The laboratory will be directed by Paul Lehman, VP and Head of QPS Dermal and Transdermal Research Services, and backed by 36 years of topical pharmacokinetics experience with the Franz Diffusion Cell. This model and associated methodologies support dermal drug development testing in the preclinical, clinical, and post-approval phases, including the in vitro rate-of-release assay based on the FDA SUPAC-SS Guidance.
The facility now offers its services to clients conducting in vitro Research & Development (non-GLP) topical pharmacokinetics and in vitro release rate studies using the Franz Diffusion Cell. The laboratory will also be offering augmenting services for studies intended for regulatory submission (with full GLP compliance).